(Q33405318)

26 July 2017

title

A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies (English)

1 reference

26 July 2017

R D Harvey

1

1 reference

26 July 2017

T K Owonikoko

2

1 reference

26 July 2017

C M Lewis

3

1 reference

26 July 2017

A Akintayo

4

1 reference

26 July 2017

Z Chen

5

1 reference

26 July 2017

M Tighiouart

6

1 reference

26 July 2017

S S Ramalingam

7

1 reference

26 July 2017

M P Fanucchi

8

1 reference

26 July 2017

P Nadella

9

1 reference

26 July 2017

A Rogatko

10

1 reference

26 July 2017

D M Shin

11

1 reference

26 July 2017

B El-Rayes

12

1 reference

26 July 2017

F R Khuri

13

1 reference

26 July 2017

J S Kauh

14

1 reference

26 July 2017

language of work or name

English

0 references

publication date

15 January 2013

1 reference

British Journal of Cancer

26 July 2017

published in

1 reference

26 July 2017

volume

108

1 reference

26 July 2017

issue

4

1 reference

26 July 2017

page(s)

762-765

1 reference

Blockade of NFκB activity by Sunitinib increases cell death in Bortezomib-treated endometrial carcinoma cells

26 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3590658

Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3590658

Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3590658

Combination Therapy of Bortezomib with Novel Targeted Agents: An Emerging Treatment Strategy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3590658

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3590658

Safety and efficacy of combining sunitinib with bevacizumab + paclitaxel/carboplatin in non-small cell lung cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3590658

Phase I study of bortezomib and cetuximab in patients with solid tumours expressing epidermal growth factor receptor

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3590658

A phase I and pharmacologic study of the combination of bortezomib and pegylated liposomal doxorubicin in patients with refractory solid tumors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3590658

Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3590658

Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3590658

Cancer phase I clinical trials: efficient dose escalation with overdose control.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3590658

Phase II study of sunitinib in patients with metastatic urothelial cancer

21 June 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FBJC.2012.604

Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3590658

Randomized Phase II Study of Bortezomib Alone and Bortezomib in Combination With Docetaxel in Previously Treated Advanced Non–Small-Cell Lung Cancer

31 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23322195

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/BJC.2012.604

1 reference

Dimensions Publication ID

26 July 2017

0 references

1 reference

26 July 2017

1 reference